Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

F. Bajorin, Dean; Alfred Witjes, J.; E. Gschwend, Jürgen; Schenker, Michael; P. Valderrama, Begoña; Tomita, Yoshihiko; Bamias, Aristotelis; Lebrét, Thierry; F. Shariat, Shahrokh; Hoon Park, Se; Ye, Dingwei; Agerbæk, Mads; Enting, Deborah; McDermott, Ray; Gajate, Pablo; Peer, Avivit; I. Milowsky, Matthew; К. Носов, А.; Neif Antonio, João; Tupikowski, Krzysztof; Toms, Laurence; S. Fischer, Bruce; Qureshi, Anila; Collette, Sandra; Ünsal-Kaçmaz, Keziban; Broughton, Edward; Zardavas, Dimitrios; Koon, Henry; D. Galsky, Matthew

doi:10.1056/nejmoa2034442

Public

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

Published in New England Journal of Medicine • Jun 2, 2021

Authors:

Dean F. Bajorin

J. Alfred Witjes

Jürgen E. Gschwend

Abstract

BACKGROUND: The role of adjuvant treatment in high-risk muscle-invasive urothelial carcinoma after radical surgery is not clear. METHODS: In a phase 3, multicenter, double-blind, randomized, controlled trial, we assigned patients with muscle-invasive urothelial carcinoma who had undergone radical su...

Subject

Urothelial carcinoma

Nivolumab

Adjuvant

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!